Sanofi-Sythelabo’s attempts to acquire Aventis  is the fact that the company just released great phase 3 data on a pill that would help stop two of the nation’s biggest killers — smoking and obesity.

The drug, rimonabant, or Acomplia, packs a wicked combination punch. It helped roughly one-third of smokers quit and without gaining weight. In non-smokers, it helps overweight people lose 20 pounds and more than three inches off their waists. Finally, Acomplia increased HDL, the so-called “good cholesterol” by 23% while reducing triglycerides by 16%. Weight loss alone usually does not increase HDL. Increasing HDL and modifying lipids other than LDL is a major goal of big pharma players like Pfizer

While only slightly more than a third of smokers quit over a year, compared to nearly 21% of placebo-treated smokers, this is a significant result and compares favorably with other smoking cessation products. Importantly, patients lost an average of a half-pound while on Acomplia, whereas patients on placebo gained over 2 pounds. And, interestingly enough, overweight smokers lost the weight, while normal weight smokers did not.

I think the weight loss data in non-smokers were even more impressive. Nearly 75% of patients lost 5% of their body weight over one year, with 44% losing more than 10%. The weight loss coupled with the changes in their lipid profiles makes this drug candidate particularly promising. As an added bonus, C-reactive protein (CRP)–a marker for heart disease– dropped by 27% and insulin sensitivity rose. Increasing insulin sensitivity is vital for preventing adult-onset diabetes (Type II diabetes) that afflicts many overweight people.

The drug seems to work on the same brain receptor that makes marijuana users crave food, scientifically termed the “munchies.” Apparently, both tobacco and overeating also affect this Endocannabinoid System, sending into disarray. Acomplia blocks the receptors in the brain in order to restore the system to balance. Unfortunately for some users, the drug also causes dizziness and nausea, leading to a 15% dropout rate for the high-dose patients in the trial.

With obesity and smoking sending about 800,000 Americans total to their graves early every year, a drug that can help treat both conditions could be a major breakthrough. As long as there are no nasty Phen-Fen-like surprises, this could be a very popular treatment among the nearly one-quarter of Americans who smoke and the nearly two-thirds of Americans who are overweight. I would expect Acomplia to be available to patients around the second quarter of next year, so you have a whole year to load up on the cake and ice cream to see if this pill will really work.

The World Health Organization estimates that more than 2.5 million deaths worldwide can be attributed to obesity each year, and the number continues to increase. Few safe and effective medications are available for obesity, but new understanding of the physiologic regulation of food intake and calorie storage have led to the development of therapies targeting the endocannabinoid system. This system is overactive in animal models of obesity and is believed to modulate food intake and adipogenesis through receptors (CB1) in the brain and a variety of peripheral tissues. Van Gaal and colleagues studied a CB1-blocking drug, rimonabant (Acomplia), in a large trial of adult obese patients.

The researchers recruited more than 1,500 obese adults from 60 European and U.S. centers. Inclusion criteria were a body mass index (BMI) of 30 or a BMI of 27 plus hypertension or dyslipidemia. Participants also were required to have experienced less than 11-lb (5-kg) variation in body weight in the three months before the study, and to be free from significant cardiovascular, pulmonary, hepatic, renal, neurologic, psychiatric, and endocrine disease, including diabetes. Participants were excluded if they had a history of surgical procedures for weight loss or of significant depression, were currently taking medications known to influence body weight, or intended to change their smoking status during the study period.

After extensive baseline assessment, including basal metabolic rate, body measurements, glucose tolerance testing, and other laboratory screening, 1,507 participants were randomly assigned to 5 mg per day of rimonabant, 20 mg per day of rimonabant, or placebo. All patients were advised on diet and exercise based on their personal basal metabolic rate. Patients were reassessed every 14 days for one month, then every 28 days for two years.

Patients in the three groups were comparable in all significant variables at baseline. Only 61 percent of participants completed the one-year follow-up: 379 (62.7 percent) in the 5-mg group, 363 (60.6 percent) in the 20-mg group, and 178 (58.4 percent) in the placebo group. Using intention-to-treat analysis, researchers found that patients taking rimonabant had significantly greater weight loss and improvement in lipids and insulin function after one year than those taking placebo. This effect was more pronounced if the analysis was limited to participants who completed one year of assigned therapy. In this analysis, the cumulative weight loss was 11 lb (5 kg) in the placebo group, compared with more than 22 lb (10 kg) in the 20-mg group. The percentage of patients with 10 percent or more weight loss was significantly greater in the 20-mg group (27.4 percent) than the placebo group (7.3 percent) but not in the 5-mg group (10.1 percent). If only those patients who completed the study were considered, these figures rose to 39 percent in the 20-mg group, 12.4 percent in the placebo group, and 15.3 percent in the 5-mg group. Waist circumference and lipid profile also improved significantly in patients taking rimonabant. The proportion of patients with metabolic syndrome decreased from 41.2 to 28.6 percent in those taking 5 mg and from 42.2 to 19.6 percent in those taking 20 mg, compared with a decrease from 39.9 to 31.4 percent in the placebo group. In about one half of participants, improvement in metabolic risk factors was independent of weight loss. Adverse effects were reported by more than 80 percent of patients in all three groups but most were mild and transitory. The greatest number of discontinuations (87) occurred in the 20-mg group, with almost one half (42) being attributed to psychiatric disturbance.

Rimonabant Acomplia is a wonder diet pill manufactured by Sanofi Aventis for weight loss treatment. Rimonabant Acomplia Zimulti has been approved by European Union in June 2006 and now has become the most popular treatment for weight loss in obese people. Rimonabant Acomplia is also known as magic drug as it helps for smoking cessation as well as heart diseases.

Rimonabant Acomplia was made marketable in the UK and rest of Europe as result of a conformity made by 25-member European Union.

Acomplia is an anti–obesity with Rimonabant, as its main constituent. Rimonabant was discovered and manufactured by a French pharmaceutical firm, Sanofi-Aventis.

It works on the principle of targeting the CB-1 receptors, found in the Endo- cannabinoid (EC) system. These receptors control food and tobacco intake in the body. When these receptors are blocked, your appetite tends to reduce. As a result you eat less than your normal appetite and therefore you loose weight. It shows maximum results when used in addition with a low calorie diet and regular work out.

There are number of pharmacies offering Generic Acomplia Rimonabant for weight loss which is available without prescription at economic Rates. We also provide you now with “Generic Acomplia Rimonabant” that can be shipping worldwide and is available on our website at abosolutely economic cost.

The drug, rimonabant, works by blocking the circuits in the brain that control the urge to eat and smoke. The drug works by blocking the endocannabinoid system in the brain which regulates hunger, and probably other urges, including craving for alcohol. The drug marijuana makes people ravenous by stimulating this circuitry.

Rimonabant is an oral anorectic prescription drug. Rimonabant works by targeting the CB-1 receptors, which are responsible for your appetite and nicotine intake. This in turn makes you eat less than your normal craving for food and nicotine

elease yourself from the burden of extra pounds with Acomplia. Acomplia Rimonabant is an ideal drug to tackle obesity, which has become a worldwide phenomenon

Acomplia Rimonabant basically points out that your BMI is greater than 30. BMI or Body Mass Index is a calculated amount of body weight in proportion to your height. The higher your BMI, the more probability you have to experience from obesity and its related health hazards. Acomplia arranged at our online drug store can make your route to get that slim and trim body efficiently. Acomplia is basically a brand name for Rimonabant, which operates as an appetite suppressant. It is developed and marketed by Sanofi-Aventis, a French pharmaceutical firm.

Acomplia weight loss drug works by inhibiting the CB-1 receptors found in the Endo-cannabinoid (EC) system, which regulates your need to eat. These receptors tend to be overactive among the obese people as a result causing obesity. Blocking of these receptors, makes you tend to eat less as compared to your normal diet, as a result leading towards weight loss. Acomplia weight loss program should be followed in combination with a reduced calorie diet and regular workout regime to realize considerable weight loss. It is always advisable to talk with your doctor before undertaking Acomplia (Rimonabant) treatment to escape any future medical complications. Acomplia diet pill is preferred over other diet drugs because of its affordability and optimistic weight loss results.

SILVER SPRING, MD, 28 June 2007 — Members of FDA’s Endocrinologic and Metabolic Drugs Advisory Committee in June agreed unanimously that rimonabant, a weight-management drug made by Sanofi Aventis, lacks adequate safety data to merit FDA approval.

“I wouldn’t in any way suggest that it be approved at the present time for use,” said committee member Jules Hirsch of Rockefeller University in New York.

Rimonabant is a selective cannabinoid-1 (CB-1)-receptor inhibitor and would have been the first in this class of drugs available in the United States. The drug inhibits the body’s endocannabinoid system, which affects appetite, energy balance, glucose and lipid metabolism, and body weight.

Rimonabant is already approved for sale in nearly 40 countries under the brand name Acomplia but would be called Zimulti in the United States, according to Sanofi Aventis.

When accompanied by a low-calorie diet, rimonabant led to significantly greater weight loss than placebo during clinical trials. Most of the weight loss occurred during the first nine months of therapy before leveling off and was accompanied by improvements in waist circumference and plasma levels of triglycerides and high-density-lipoprotein cholesterol.

Although FDA stated that the weight loss from rimonabant was clinically and statistically significant, the agency expressed concerns about rimonabant’s safety profile—in particular, the neurologic and psychiatric adverse events that were frequently reported in clinical trials of the drug.

Amy Egan, an FDA medical officer, told the panelists that adults who received a once-daily 20-mg dose of rimonabant, the amount effective for weight loss, were about twice as likely as placebo recipients to report psychiatric effects such as depression, anxiety, suicidality, and other cognitive and neurologic symptoms.

“The vast array of these events gave us a considerable sense of uneasiness,” Egan said, adding that rimonabant recipients were more than twice as likely as placebo recipients to drop out of clinical trials because of psychiatric symptoms.

Patients with a significant history of depression were excluded from clinical trials of rimonabant, even though overweight and obese people are believed to be at great risk for depression.

Egan said that 8.5% of rimonabant recipients began taking an anxiolytic or hypnotic and 4.8% began antidepressant treatment during clinical trials—roughly double the percentages who initiated these therapies while taking placebo. She noted that 88% of participants in the major rimonabant trials who reported neuropsychiatric symptoms while receiving the drug had no prior history of depressive symptoms.

Sanofi Aventis had proposed creating a risk-management program for rimonabant in the United States to prevent people with depression from taking the drug.

After the meeting, the manufacturer released a statement saying that it planned to work closely with FDA to resolve the committee members’ concerns about rimonabant.

An FDA decision on rimonabant is expected on July 27. Although FDA is not required to take the committee’s advice and reject the manufacturer’s application, the agency usually follows the recommendations of its experts.

Shannon Finks, a cardiology specialist and assistant professor at the University of Tennessee College of Pharmacy in Memphis, said the meeting’s outcome was “a big disappointment for the 60% of all Americans who are overweight or obese that could benefit from cardiometabolic risk reduction.”

“I had high hopes for this agent,” she said. But, she added, “I am certain that the advisory panel—hearing, seeing, and analyzing all data—made the right decision at this time to keep patients out of harm’s way.”

Finks, whose practice site is the Memphis Veterans Affairs Medical Center, is especially interested in the treatment of metabolic syndrome, a condition that is characterized by abdominal obesity, abnormal plasma triglyceride levels, and insulin resistance.

“Sixty percent or [more] of our patients are overweight,” Finks said. “We deal with the complications of being obese and having metabolic syndrome every single day.”

Sanofi Aventis had initially sought FDA’s approval to market rimonabant for the treatment of metabolic syndrome, according to FDA, but the agency stated that clinical data on the drug did not adequately support that indication.

Finks said that losing just a little bit of weight can improve patients’ cardiometabolic risk profiles.

“If you lose 5–10% of your body weight, we know that lipid parameters improve, we know that blood pressure decreases, we know that triglycerides decrease,” Finks said. “We know that you have an overall improvement in health.”

But Finks emphasized that neither rimonabant nor any other weight-loss drug should be the cornerstone of a program to help people lose weight.

“Lifestyle modification is the number-one treatment for metabolic syndrome and obesity,” Finks said. “Pharmacotherapy is not the answer. Pharmacotherapy can be used, though, with diet and exercise.”

Amy Franks, assistant professor at the University of Arkansas for Medical Sciences College of Pharmacy in Little Rock, emphasized that health care practitioners need to view weight management as a lifelong issue.

“We should be thinking about obesity as a chronic illness and treating it with the same vigor that we treat someone who’s hypertensive or someone who has diabetes or someone who has hyperlipidemia,” she said.

Franks, who recently completed a pilot study of a pharmacist-run program to identify and counsel adults with metabolic syndrome, said she is not a big proponent of pharmcotherapy for most patients.

Acomplia (rimonabant) is the first medication in a class known as endocannabinoid CB1 receptor antagonists to be approved in the UK. This makes Acomplia a revolutionary way of tackling obesity and it has been prescribed to over 100,000 people in Europe since its launch in June 2006.

Acomplia is a prescription medication so you must complete an online consultation form before you can purchase this medication. Consultations are free and you are under no obligation to make a purchase.

Little is known about the endocannabinoid system as it has only recently been discovered and explored but it is believed to regulate energy consumption and expenditure. The endocannabinoid system comprises (amongst other components) cannabinoids (chemical signals) and CB receptors. The CB1 receptors are located in the brain, certain organs and peripheral tissues such as fat cells. Cannabinoids, naturally occurring chemicals produced by the body, attach themselves to CB1 receptors, at which point a signal is transmitted, indicating to the brain that we should eat something. Studies have demonstrated that the endocannabinoid system tends to be more active in overweight people. In simplistic terms, Acomplia (Rimonabant) prevents the CB1 receptors from working in an overactive way, thereby helping to regulate and normalise the operation of the endocannabinoid system, which should, in turn, allow overweight people to lose weight.

Acomplia (Rimonabant) was tested on 6800 volunteers during the phase 2 and phase 3 clinical trials. The phase 3 trial lasted for two years and was compared with a placebo control group. Both groups were asked to increase their level of physical activity. It was demonstrated that those taking Acomplia lost on average 4 times more weight than those taking the placebo. Most of the weight loss occurred in the first 9 months of treatment but the weight loss was maintained until the end of the two year trial. Acomplia does not work for everyone but just over 50% managed a weight loss of 5% and approximately 27% managed a weight loss of 10% or more of their overall body weight.

The study comprising the phase 3 clinical trial demonstrated that waist circumference was reduced. An expansive waist circumference is thought to be a marker for the visceral fat which has been linked to diabetes and heart disease. It was also demonstrated that patient cholesterol levels were improved beyond that which would normally be expected from weight loss alone after being treated with Acomplia. There is also evidence to suggest that Acomplia (Rimonabant) might be effective in helping people who want to give up smoking although it has not been approved for this purpose. If you are looking for help in giving up smoking, we will happily provide you with a free consultation for a smoking cessation aid. We are only prepared to prescribe Champix as a smoking cessation aid as we believe that this is the safest and most effective treatment currently available.

Acomplia Information

Although clinical studies on the drug have shown that smoking habits have improved and craving for nicotine has considerably reduced in patients, Acomplia rimonabant has not been licensed as an anti-smoking drug in UK. It has been only approved to be used in anti-obesity treatment. We strongly advise you to seek a face to face consultation with your doctor as this is a prescription medication. Your family doctor or certified medical practitioner knows the best for you and we recommend that you follow their advice. Our service is not a substitute for the same.

The most awaited slimming pill in the weight loss drug segment is finally here. Acomplia has succeeded in entering the European markets with European Union’s nod to market it as an anti-obesity drug. Two years of successful clinical trials have finally paved the way for people looking at anti-obesity treatments to buy Acomplia (Rimonabant) as a means to control obesity. Acomplia is also helpful in controlling smoking amongst its positive side effects.

What is Acomplia?

Acomplia works directly on the urge or craving to eat more. This is accomplished by working on the endocannabinoid system, a system affecting energy balance, glucose and lipid metabolism and body weight. Blocking certain receptors in the brain will result in the patient experiencing the feeling of being full thus wanting to eat less than normal. Along with using in conjunction with a calorie reduced diet and exercise it significantly helps obese patients achieve a weight loss.

What are the benefits of Acomplia Rimonabant?

Along with effective weight loss, Acomplia discourages bad habits like smoking. It is also an anti-smoking pill and improves HDL(good cholesterol) and triglyceride levels. This benefits diabetes and heart conditions. Usual dosage recommended is 20mg per day based on the advise of your doctor depending on your health.

What are the side effects of Acomplia Rimonabant?

No pill is without side-effects. Acomplia has a few minor side effects which are very temporary and transient. These include nausea, dizziness, diarrhea, vomiting, hypoglycaemia, anxiety and mood swings.

Acomplia is a promising new drug with a wide range of possibilities of application to various diseases and health problems.

Cheap rimonabant is an oral prescription medication, which should be taken only on doctor’s advice. Generally doctors prescribe 20mg pills of Cheap rimonabant, which should be taken with one glassful of water. This medication produces better results when it is taken on empty stomach that is the reason why most doctors suggest for taking the pill an hour before breakfast. Breaking of rimonabant(Cheap rimonabant) pills can produce some unnecessary changes in chemical structure of the medication so it must not be chewed.It is the popularity of the medication that some unknown company has introduced a drug by the Acomplix in the weight loss drug market. But user of rimonabant approved should be aware of such duplicate and ineffective copies of this powerful medication as they may cause some harms.The rimonabant approved drug may have some mild side effects like dizziness, constipation, nausea, dry mouth and stomach disorder. The side effects are limited to the use of drug for initial period only because of non-adjustment of the body to the medication. Generally side effects disappear with the regular use of this beneficial medication for few days. rimonabant approved is not meant for the pregnant ladies and breast-feeding mothers.rimonabant is easily available through an online order; the delivery of product is made at your doorstep. Nearly every large-cap pharma is attempting to deal with the prospect of generic competition for its top drugs, and Sanofi-Aventis (NYSE: SNY) is no different. Its $3-billion-a-year blood thinner, Lovenox, is potentially facing generic competition as early as next year.To help fill the void left by the loss of patent exclusivity on its top drugs, Sanofi has rapidly been ramping up sales of its Ambien insomnia treatment franchise, as well as trying to bring to market its weight-loss drug, rimonabant.On Friday, Sanofi announced that the FDA has set April 26 as the new date to review rimonabant and give Sanofi a thumbs-up or -down on marketing it in the U.S. Back in February, the drug received an approvable letter for its weight-loss indication and was deemed non-approvable as a treatment to help people stop smoking.Rimonabant release was approved in the European Union back in late June, but the U.S. is where the big money is,rimonabant release especially now that France and Germany have been enacting new measures such as higher taxes on drug sales and rules to encourage doctors to prescribe cheaper prescriptions or generic drugs.(rimonabant release*)

NEW YORK (AP) — An HSBC analyst upgraded Sanofi-Aventis SA Wednesday, citing the French drug maker’s full pipeline and shrugging off its failure to receive U.S. approval for the weight-loss drug rimonabant study.

In late June, Sanofi-Aventis withdrew its application to gain U.S. approval for rimonabant study, following a meeting in which government advisers rejected the treatment on safety grounds. The Paris-based company said it would resubmit its Food and Drug Administration application for rimonabant study at a later date.Despite the rimonabant issues, HSBC analyst Kevin Scotcher on Wednesday raised his rating on Sanofi shares to “Overweight” or “Buy” from “Neutral,” citing the company’s new drug portfolio.”Given the share price decline post the failure to commercialise rimonabant in the U.S. in 2007, we nonetheless point out that Sanofi has numerically the fullest pipeline among the 11 U.S. and European drug majors under our coverage,” Scotcher wrote in a note to investors.HSBC did lower its price target on the shares to 71 euros ($98) from 72.50 euros, however. The analyst pointed to risks including the possibility that Sanofi could launch a highly leveraged takeover of American rival Bristol-Myers Squibb Co.The uncertain future for rimonabant weight loss raises pressure on the French drug maker to make acquisitions to boost its drug portfolio, analysts have said.Scotcher said generic versions of Plavix, which is Bristol-Myers Squibb Co.’s best selling product, could enter the market before patent expiration. Sanofi-Aventis sells Plavix in the United States through Bristol-Myers.Shares of Sanofi-Aventis fell 26 cents to $42.45 in afternoon trading on below-average volume. Shares of Bristol-Myers fell 31 cents to $31.84 in afternoon trading, but earlier in the day hit a 52-week high of $32.35.

Anti-obesity drugs are the prime requirement of millions of obese across the world. Only an obese knows well about the problem related with obesity. Every third person tries to instruct an obese what to eat and what not to. There are people who laugh at an obese. Every obese knows that obesity can be cured with the help of suppression of appetite and proper exercising. Both things are easy to suggest but difficult to do. Exercising needs time and where is the time in the busy schedule to do rigorous exercising? How can an obese suppress appetite when urge for food is acute?

Appetite can be effectively suppressed with the aid of appetite suppressing drugs(rimonabant weight loss). The list of such drugs is long but most of them are in the weight loss drug market for years and obesity is still there. This puts a big question mark on the efficacy of those appetite suppressants. Recently, Sanofi-Aventis a drug manufacturing company of France has launched a new medication in the European anti-obesity drug market.This drug is introduced by name of rimonabant weight loss and was initially launched in the UK drug market where countless obese found it very effective. rimonabant weight loss is a product of advance drug development technology whose line action of is quiet different from almost all anti-obesity medication available in the market. Cells of our body have neurotic receptors named as cannaboid receptor-1; this receptor is responsible for the transmission of hunger signal to the brain. The substance, which can block the working of CB-1 receptor, can be a proven appetite suppressant. 2006 rimonabant’s active ingredient Rimonabant 2006 does this work. rimonabant can also help in the cessation of smoking by inhibiting the working of the CB-1 receptor. Tags:rimonabant 2006,[rimonabant study],(rimonabant weight loss)

What Is Rimonabant?

A single pill Rimonabant has been found to stop food craving enough to help people lose weight, and could also help curb other unhealthy urges. Named Rimonabant Acomplia the drug in one study helped people who were overweight drop an average of 20 pounds and very useful for the patients who suffer from obesity. Rimonabant Acomplia is made by French firm Sanofi-Synthelabo and the company says it is available now in Europe. Acomplia contains the active ingredient Rimonabant. It is a selective CB1 endocannabinoid receptor antagonist.

How does Rimonabant (Acomplia) work?

Rimonabant Acomplia online works by blocking receptors of a substance called cannabinoid 1, which stimulates hunger and other cravings in the brain and is also present in fat tissue. This receptor is also present in the fat tissue and controls the hunger in the brain. So when you take this rimonabant drug, you will automatically eat less because you do not feel hunger. As a result you will take less food which helps you to reduce your cholesterol levels. When you start losing weight, the first place you will lose body fat is your mid-section. And your cholesterol will go down and your blood pressure will return to healthy levels.

Rimonabant Side Effects.

Rimonabant Acomplia (diet drug) was said to be well tolerated in early tests. The only relatively common side effects were mild GI side effects and dizziness, and these were said to be transient.

A Miracle? Rimonabant Acomplia - a real pharmaceutical help for weight loss, metabolic syndrome, and HDL levels may be on the horizon . It is thought that Rimonabant Acomplia is available from 28th june 2006.And you can buy Rimonabant Acomplia online through prescription given by our doctor.

Please note that Rimonabant Acomplia is available to purchase, you can buy it anywhere as it has been released!

 Why does weight loss (obesity) matter?

Despite being a very common condition being obese or overweight can have serious effects. Obesity can lead to extremely serious health problems, including arthritis, heart disease and diabetes. Because of this, in England , over 30,000 deaths a year are caused by obesity. It has been estimated that obesity costs the NHS £500 million a year. The overall cost to the country is thought to be over £7 billion every year.

Treatment of obesity or the promotion of weight loss with Acomplia (Rimonabant)

As discussed above the best way to guarantee weight loss is to consume fewer calories and take more exercise. In addition to these doctors can now prescribe Acomplia, which has been shown to assist in weight loss.

When can Acomplia (Rimonabant) be prescribed to help weight loss (obesity)?

Acomplia is licensed as an adjunct to diet and exercise to promote weight loss. It is a prescription only medicine which can be prescribed for obese patients with a body mass index (BMI) of greater than 30 kg/m 2 or for overweight patients with a body mass index (BMI) of greater than 27 kg/m 2 who also have other risk factors such as type 2 diabetes or dyslipidaemia (a disturbance in the levels of fat (lipids) in the blood).

How many people are over weight or obese?

People are classed as obese if they have a body mass index over 30. They are overweight if it is 25-30.

Adult obesity rates have almost quadrupled in the last 25 years. Now over 20% of Britons are obese and three-quarters are classed as overweight.

What are the causes of obesity?

In most otherwise healthy people, the causes of being obese or overweight are simple: eating too many calories or taking too little exercise, or more than likely a combination of both!

The plethora of fad diets have convinced many people that eating low fat or low carbohydrate foods can provide a short cut to losing weight. Your body has the capability to convert fat to carbohydrates and carbohydrates to fat depending on the quantity of each it has available to it, so manipulating the amount taken in the diet in an attempt to lose weight is largely useless. In otherwise healthy people, it is equally untrue that some people have a “slow metabolism” and so are more likely to put on weight.

The simple fact is that if you regularly consume more calories than you burn off, you will put on weight. The good news is that if you burn off more calories than you consume on a regular basis you WILL lose weight. The only guaranteed way to lose weight is therefore to eat less, do more and preferably do both.